| Released | Contributor | Author | Title | Pages | Price |
| 15-Dec-2009 | New Constructs, LLC |
N/A
| IMGN: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 15-Dec-2009 | EconomicInvestor |
N/A
| "The Economy Matters" Report for IMGN: the economy's impact on IMGN's price and risk, featuring the powerful EconomicInvestor Star Rating | 6 |
$15 |
| 15-Dec-2009 | Pechala's Reports | Lubomir Pechala | IMMUNOGEN INC (IMGN=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 14-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 14-Dec-2009 | Thomson StreetEvents |
N/A
| IMGN - Event Transcript of ImmunoGen, Inc. conference call, Dec. 14, 2009 / 8:00am ET | 15 |
$75 |
| 14-Dec-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 14-Dec-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 14-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for IMGN | 13 |
$25 |
| 14-Dec-2009 | Market Edge |
N/A
| Market Edge Equity Research Report | 4 |
$10 |
| 13-Dec-2009 | PriceTarget Research, Inc. |
N/A
| ImmunoGen has a current Overall Rating of F (Lowest Rating). | 7 |
$25 |
0.39% Nasdaq 
Research Reports
